Antibiotic research and development: business as usual?
| Autor: | Harbarth, S, Theuretzbacher, U, Hackett, J, collaborators: Adriaenssens, N, Anderson, J, Antonisse, A, Årdal, C, Baillon-Plot, N, Baraldi, E, Bettiol, E, Bhatti, T, Bradshaw, D, Brown, N, Carmeli, Y, Cars, O, Charbonneau, C, Cheng, S, Ciabuschi, F, Cirino, J, Clift, C, Colson, A, Dane, A, De-Lima, N, Dooa, M, Drabik, D, Eisenstein, B, Farquhar, R, Fidan, D, Findlay, D, Galli, F, Gilchrist, K, Gilman, S, Goeschl, T, Goodall, J, Goossens, H, Gouglas, D, Guise, T, Gyssens, I, Hallerbäck, P, Heymann, D, Hoffman, S, Howell, J, Hulscher, M, Hunt, T, Huttner, B, Jantarada, F, Jaquest, D, Joly, F, Ka, L, Karas, A, Knirsch, C, Kullberg, Bj, Laxminarayan, R, Le Maréchal, M, Legros, S, Lilliott, N, Lindgren, E, Longshaw, C, Mahoney, N, Mastrangelo, D, Mcdonald, J, Mckeever, S, Mepham, T, Milanic, R, Monnier, A, Morel, C, Morton, A, Mossialos, E, Nolet, B, Outterson, K, Payne, D, Piddock, L, Plahte, J, Potter, D, Pulcini, C, Rex, J, Ross, E, Rottingen, Ja, Ryan, K, Ryan, J, Salimi, T, Schouten, J, Schultz, S, So, A, Spiesser, J, Stålhammar, No, Stanic, M, Tacconelli, E, Temkin, L, Trick, D, Vink, P, Vlahovic-Palcevski, V, Watt, M, Wells, M, Wesseler, J, White, A, Wood, S, Zanichelli, V, Zorzet, A. |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Microbiology (medical)
antimicrobial agents clinical studies drug development economics global health policy multidrug resistance patient safety Anti-Bacterial Agents Drug Discovery Drug Industry Humans Motivation Research medicine.drug_class Economic policy Economics Antibiotics WASS Drug development Multidrug resistance Patient safety Antibiotic resistance medicine Agricultural Economics and Rural Policy Pharmacology (medical) Pharmacology ddc:616 Agrarische Economie en Plattelandsbeleid Investment (macroeconomics) Antimicrobial agents Infectious Diseases Incentive lnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4] Economic model Business Anti-Infective Agents Clinical studies Global health policy |
| Zdroj: | Journal of Antimicrobial Chemotherapy, 70(6), 1604-1607 Journal of Antimicrobial Chemotherapy, Vol. 70, No 6 (2015) pp. 1604-7 Journal of Antimicrobial Chemotherapy, 70, 6, pp. 1604-7 Journal of Antimicrobial Chemotherapy, 70, 1604-7 Journal of Antimicrobial Chemotherapy 70 (2015) 6 |
| ISSN: | 1604-1607 0305-7453 |
| DOI: | 10.1093/jac/dkv020 |
| Popis: | The global burden of antibiotic resistance is tremendous and, without new anti-infective strategies, will continue to increase in the coming decades. Despite the growing need for new antibiotics, few pharmaceutical companies today retain active antibacterial drug discovery programmes. One reason is that it is scientifically challenging to discover new antibiotics that are active against the antibiotic-resistant bacteria of current clinical concern. However, the main hurdle is diminishing economic incentives. Increased global calls to minimize the overuse of antibiotics, the cost of meeting regulatory requirements and the low prices of currently marketed antibiotics are strong deterrents to antibacterial drug development programmes. New economic models that create incentives for the discovery of new antibiotics and yet reconcile these incentives with responsible antibiotic use are long overdue. DRIVE-AB is a €9.4 million public–private consortium, funded by the EU Innovative Medicines Initiative, that aims to define a standard for the responsible use of antibiotics and to develop, test and recommend new economic models to incentivize investment in producing new anti-infective agents. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|